Read our latest news, and find more about us and our portfolio companies.

Neurable raises $6 million to develop brain-sensing consumer devices, beginning with headphones

Neurable raises Series A to build an “everyday” brain-computer interface


Forendo Pharma today announces signing of a License and Collaboration Agreement with Novartis.

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

- Clinical trial collaboration agreement leverages NEC’s cutting-edge AI technology and VAXIMM’s novel oral T-cell immunotherapy technology - NEC to make an equity investment in VAXIMM

Plexium Launches with $28 Million in Series A Financing

Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases

Artios Pharma appoints Tania Dimitrova as Chief Business Officer and expands presence in the United States

Artios Pharma Limited (Artios) announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.

Riffyn Appoints Former Cisco and HP Executive Barbara Adey to Board of

Adey Brings Deep Enterprise Software and Sales Leadership

Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate

Forendo Pharma today announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo

BASF is collaborating with Riffyn on white biotechnology R&D

Next-generation global data platform to advance development of bio-based solutions and fermentation processes

John Conway, Former Head of Data Sciences and AI at AstraZeneca, Joins Riffyn as Chief Commercial Officer

A recognized scientific informatics pioneer, Mr. Conway brings to Riffyn extensive experience transforming scientific data environments and analytics

Larry Peck, Former VP at Autodesk, Joins Riffyn as Vice President of Engineering

Mr. Peck brings to Riffyn extensive experience as Autodesk Vice President Global Engineering, and Head of Life Sciences

Riffyn Enters Multi-Year Contract with Novozymes for R&D Data Analytics

Riffyn announces a multi-year partnership with world-leading biotech company Novozymes

Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy

Riffyn Raises a $15M Series B to Accelerate Its Growth in Life Sciences R&D

Riffyn, a global provider of Software-as-a-Service (SaaS) for scientific process design and data analytics, announces the close of a $15 million Series B financing led by M Ventures with participation from Waters Corporation, O’Reilly AlphaTech Ventures, and Plug and Play Ventures. Funds will be used to globally expand sales and scientific services, and to accelerate development of Riffyn’s process development and advanced data analytics technology.

DNA Script Raises $38.5 Million in Series B Financing

Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.

GE Healthcare and Indi Molecular to collaborate on diagnostic tool for clinical management of immunotherapy patients

● The companies will work together to develop non-invasive Positron Emission Tomography (PET) imaging agents (tracers) targeting CD8, focused on marking cytotoxic T lymphocytes, key predictors of immunotherapy response.

Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology

Sonde Health Inc. today announced the completion of a $16 million Series A financing round, including the issuance of $6 million in shares upon conversion of debt into equity.

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

**Establishes New Clinical Advisory Board of Leading Oncology Experts**

iOnctura selected for an oral presentation at 2019 AACR Annual Meetin

iOnctura SA announced today that its abstract (abstract # 1781) “Preclinical development of a novel, highly selective PI3Kδ inhibitor" has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019.

Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED)

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors

M&A of the Year: Prexton Therapeutics

Having emerged from the Merck Serono Entrepreneur Partnership Program (EPP) in 2015, Prexton Therapeutics raised a total $41m of funding before it was acquired by pharmaceutical firm Lundbeck for an estimated $1.1bn last year.

Asceneuron appoints Peter Van Vlasselaer as Chairman

Asceneuron appoints Peter Van Vlasselaer as Chairman Serial biotech entrepreneur joins leading small molecule tau modulation company